Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
XRAY · Nasdaq · United States · Dental Equipment & Supplies
In shortDENTSPLY SIRONA Inc. is loss-making, generates cash and carries moderate debt, with revenue shrinking (−3.0% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -11.5% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -16.3% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -36.5% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -9.1% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.51× | 59/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.74× | 15/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -4.80× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.30 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 2.8% | 31/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 13.8% | 60/100 |
| Operating margin volatility | 16.0% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -2.1% | 5/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 4,231 | 3,922 | 3,965 | 3,793 | 3,680 |
| Cost of revenue | 1,884 | 1,795 | 1,879 | 1,835 | 1,840 |
| Gross profit | 2,347 | 2,127 | 2,086 | 1,958 | 1,840 |
| Research & development | 171 | 174 | 184 | 165 | 150 |
| Selling, general & admin | 1,551 | 1,589 | 1,613 | 1,605 | 1,438 |
| Operating income | 608 | (937) | (85) | (879) | (422) |
| Interest expense | 61 | 65 | 81 | 69 | 88 |
| Pre-tax income | 545 | (1,055) | (175) | (936) | (486) |
| Income tax | 134 | (105) | (43) | (26) | 112 |
| Net income | 411 | (950) | (132) | (910) | (598) |
| Diluted EPS | $1.87 | −$4.41 | −$0.62 | −$4.48 | −$3.00 |
| Diluted shares (millions) | 220 | 216 | 212 | 203 | 199 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−0.30 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026